Remove 2018 Remove Individual Remove Management Remove Patient-Centered
article thumbnail

Utilization of Treatment for Chlamydia and Gonorrhea in the Primary Care Setting Using the American Family Cohort [Infectious diseases (not respiratory tract)]

Annals of Family Medicine

Since untreated cases can have severe health consequences, non-adherence to the Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment guidelines (CDC) remains a concern. Study Design and Analysis: A retrospective cohort from 2018-2022. treatment rates, respectively.

article thumbnail

Comorbidities Influence Optic Outcomes in NMOSD

Physician's Weekly

Data was collected from 22 centers across North and South America, Asia, and Europe, following STROBE reporting guidelines. The dataset, acquired between 2000 and 2018, comprised OCT and clinical metadata. The AQP4-NMOSD individuals with CVC/RF had higher ON relapse rates than those with AID (1.06 ± 3.33

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog

Peter Marks at James Valentine ’s FDA Rare Disease Town Hall session at the DIA Annual Meeting last month (see Pink Sheet coverage here ), this Hub is intended to serve as the Center of Excellence that we in the rare disease community have been calling for its establishment over the last several years.

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

19:05 Clarifying the “ethics vs science” argument and critiquing research techniques 22:00 Resurgence of race-based speculation in COVID-19-related research 25:57 Implantation of ideas about innate racial inferiority within medicine 28:32 Will removal of race from algorithms potentially harm our patients?

Clinic 52
article thumbnail

District Court Interprets EKRA

FDA Law Blog

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. These lab tests are performed for physicians, substance abuse treatment centers and other types of organizations.

article thumbnail

A prophylactic treatment for hemophilia that you should know about

PEMBlog

Cristina Tarango, director of the Hemophilia Treatment Center at Cincinnati Children’s and Lisa Littner, Project Manager at Cincinnati Children’s who helped me research and write this post. Emicizumab (Hemlibra) was approved in 2018 for routine bleeding prophylaxis in hemophilia A with or without inhibitors.

article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. Our last podcast was with Laura Petrillo in 2018 – 5 years ago seems ancient history – though many of the points still apply today (e.g. Goldilocks zone).